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1025-44 Is the ICHOR Platelet Works Test as Valid as Flow 
Cytometry to Assess the Efficacy of Platelet 
Glycoprotein IIb/IIIa-Receptor Inhibitors in Patients 
Undergoing Percutaneous Coronary Intervention?
Jochem W. van Werkum, Wim BM Gerritsen, Hans C. Kelder, Fred JLM Haas, Jurriën M. 
ten Berg, Sint Antonius Hospital, Nieuwegein, The Netherlands
Background
Inhibition of the glycoprotein (GP) IIb/IIIa receptor on platelets by tirofiban and abciximab
has shown to reduce ischemic complications in patients undergoing elective percutane-
ous coronary intervention (PCI). The effect of GP IIb/IIIa antagonists can be measured by
flowcytometry, but it is a labour intensive and expensive method. The ICHOR platelet-
works is a quick and inexpensive method for measuring platelet aggregation. The ICHOR
method determines a reference platelet count in 1 ml blood in a tube containing K3-EDTA
as the anticoagulant. This process is repeated with a second tube with blood containing
20 µmol/L ADP. In the presence of ADP, platelets associate and aggregate. The ratio
between the numbers of platelets in the two tubes that did not aggregate is calculated as
percent platelet aggregation. The purpose of this study was to compare the results of
these two methods in patients treated with abciximab or tirofiban.
Methods
We randomised 40 AMI patients to abciximab (Group A, N=20) and to tirofiban ( GroupB,
N=20). Before, immediately after, 30 minutes after, 60 minutes after and 120 minutes
after PCI, bloodsamples were obtained and tested with the ICHOR test (platelet aggrega-
tion) and with flowcytometry (Biotex GP IIb/IIIa receptor occupancy kit). Correlation was
tested between the median values of flowcytometry and the ICHOR test for abciximab
and tirofiban with the use of Pearsons correlation.
Results
In Group A, GP IIb/IIIa receptor occupancy was at the different time points respectively:
0%, 86%, 90 %, 87 % and 88% and platelet aggregation was respectively: 63%, 31%,
40%, 43% and 52%. In Group B, GP IIb/IIIa receptor occupancy was at the different time
points respectively: 0%, 60%, 56%, 51% and 51% and platelet aggregation was respec-
tively: 68%, 77%, 77%, 80% and 81%.
No significant correlation between GP IIb/IIIa receptor-occupancy and platelet aggrega-
tion was found between both groups at the different time points. (Abciximab: r =0,090;
tirofiban: r =-0,031)
Conclusion
As compared with “the gold standard” flowcytometry, the ICHOR plateletworks method is
not useful to monitor de level of GP IIb/IIIa-receptor occupancy in patients treated with
abcixmab or tirofiban.
1025-45 Preprocedural Statin Medication Reduces Small and 
Large Periprocedural Myocardial Injury in Patients With 
Stent Implantation
Michael Haude, Joerg Herrmann, Lothar Volbracht, Thomas Konorza, Christoph 
Altmann, Rainer Schulz, Gerd Heusch, Raimund Erbel, University Hospital Essen, 
Essen, Germany, Mayo Clinic, Rochester
Background: Stenting-related myocardial injury (MI) is caused by microembolisation of
platelet aggregates and plaque debris together with inflammation. The pleiotropic effects
of HMG-CoA reductase inhibitors (statins) include anti-thrombotic and anti-inflammatory
aspects. Thus, we tested whether pre-procedural statin therapy limits the extent of peri-
procedural MI.
Methods: We stratified 1218 consecutive patients (pts)with uncomplicated stenting
according to their pre-procedural status of statin therapy (1012 statin-pos. and 206 statin-
neg. pts). Peri-procedural MI was assessed by analysis of creatine kinase (CK; upper
limit of normal (ULN) 80 IU/l), CK-MB (threshold ULN >8% of CK fraction) and cardiac
troponin I (TI; threshold 0.1 mg/L) before, 6, 12, and 24 hours after the intervention.
Results: Baseline characteristics including lipid levels were similar between statin-pos.
and statin-neg. pts. Postinterventional maximum CK, CK-MB, and TI elevations were
larger in statin-neg. pts (68±62 vs 52±46 IU/L; 24±20 vs 18±18 IU/L; and 0.46±0.48 vs
0.38±0.42mg/L; all p<0.001). Statin pretreatment reduced the relative risk for MI for all
cut-off criteria separating small, intermediate and large MI.
Conclusions: Pre-procedural statin therapy reduces stenting-related MI independent of
the ischemia marker and the cut-off levels with relative risk reductions (RRR)ranging 30
to 75%. 
1025-46 Prior Statin Therapy Reduces Myocardial Injury in 
Patients Undergoing Rotational Atherectomy
Edward J. McNulty, Gary Spektor, Eric Chou, Manish Parikh, Robert Minutello, Geoffrey 
Bergman, Frank Iacovone, Mun K. Hong, S. Chiu Wong, Weill Cornell Medical Center, 
New York, NY
Background: Extensive microembolization occurs during rotational atherectomy (RA),
which contributes to high rates of post-procedure cardiac enzyme elevation. We hypothe-
sized that statin therapy might ameliorate the deleterious effects of microembolization
during RA and reduce post-procedural enzyme elevations.
Methods: We studied 230 consecutive patients who underwent coronary interventions
utilizing RA between September 2000 and April 2003. Patients with renal insufficiency or
with elevated cardiac troponin I (cTnI) or creatinine kinase (CK) prior to RA were
excluded. Baseline, procedural, and post-procedural outcomes were compared for those
patients on statin therapy prior to RA and for those not on statin therapy.
Results: Baseline characteristics were similar between the two cohorts. There was no
significant difference in the use of stents or IIb/IIIa inhibitors. Patients on statin therapy
had significant reductions in mean peak cTnI and in the rate of elevated cTnI (> 1.5 ng/
ml) following the procedure. On multivariate analysis, lack of statin therapy was the only
independent predictor of cTnI elevation. 
Conclusions: Patients on statin therapy prior to RA had a nearly 50% reduction in the 
rate elevated cTnI post-procedure. Statin therapy maintained its cardioprotective effect 
even though the majority of patients received IIb\IIIa inhibitors during the procedure. 
These results further demonstrate the cardioprotective effect of statins in coronary inter-
ventions.
1025-63 Acute and Early Changes in Plasma Vascular Growth 
Factors and Circulating Endothelial Progenitor Cells in 
Patients With Acute ST Elevation Myocardial Infarction
Yongzhong Wang, Hans E. Johnsen, Erik Jørgensen, Jens Kastrup, Rigshospitalet, 
Copenhagen, Denmark, Herlev Hospital, Copenhagen, Denmark
Background: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF) show strong angiogenic effects in ischemic myocardium. Circulating bone mar-
row-derived endothelial progenitor cells (EPCs) can augment neovascularization in
ischemic tissue. We evaluated their roles for myocardial repair in patients with acute ST-
elevation myocardial infarction (STEMI).
Methods: Circulating EPCs and plasma VEGF/bFGF levels were examined in 20 STEMI
patients undergoing percutaneous coronary intervention within 12h of the symptoms.
Blood samples were obtained within the initial 24h after admission and day 3,7,14,21 and
28. 15 age and sex-matched individuals with angina, but with normal coronary angiogra-
phy, were included as controls.
Results: Plasma VEGF levels decreased approximately 50% within the initial 24 hours
and increased to a level twice the level in controls two weeks after STEMI. The plasma
bFGF levels and circulating EPCs at different time points after admission were not signif-
icantly different from the controls. However, within the patients with STEMI, plasma bFGF
level (pg/ml) increased on day 7, 14, 21 and 28 compare to day 1 on admission (P<0.05
for all).
Conclusion: The elevated plasma VEGF and bFGF levels in the subacute phase after
acute STEMI might be an indicator of the initiation of restoring angiogenesis in the inf-
arcted myocardium. No cardiac signal seems to initiate the mobilization of stem cells
from the bone marrow for vasculogenesis in the infarcted myocardium.
Not on Statin Therapy 
(N= 83 )
On Statin Therapy
(N= 147)
P Value
Patient Characteristics
Diabetes 21 % 25 % .42
Prior CABG 15 % 22 % .14
Unstable Angina 31 % 37 % .35
Procedural Findings
New Stent Placed 65 % 70 % .43
IIb\IIIa Inhibitor use 81 % 79% .74
Outcomes
cTnI Elevation 47% 26% .001
Mean Peak cTnI (ng/ml) 3.7 ± 7.4 1.8 ± 4.3 .01
CK Elevation 9.6% 4.8% .15
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1025-64 Long-Term Clinical Outcome of Catheter-Based 
Intramyocardial Autologous Bone Marrow Cells 
Implantation in Patients With End-Stage Coronary 
Artery Disease
Hung-Fat Tse, Sukumaran Thambar, Yok-Lam Kwong, John KF Chan, Gladys Lo, Chi-Lai 
Ho, Wai-Hong Chen, Grey Bellan, Chu-Pak Lau, University of Hong Kong, Queen Mary 
Hospital, Hong Kong, Hong Kong, Hunter Heart-Lung Research Guild, John Hunter 
Hospital, Newcastle, Australia
Background: Recent experimental studies have demonstrated bone marrow cell (BMC)
implantation induces neovascularization and improves heart function after myocardial inf-
arction. Despite enthusiasm for these pioneering clinical trials, the long-term safety and
efficacy of implanting autologous BMCs into the human myocardium remains a major
concern. The purpose of this study was to evaluate the long-term clinical outcome of
implanting autologous BMCs into patients (pts) with end-staged coronary artery disease
(CAD). Methods: We evaluated the long-term clinical outcome in 12 pts (mean age:
60±10 yrs, 11 males) with end-staged CAD who underwent catheter-based autologous
BMC cells implantation guided by electromechanical mapping. A mean of 1.1±0.2 ml of
mononuclear cells (106 cells/ ml, 2.9±2.6% of CD34+ cells) was injected to 16 ischemic
regions. No elevation in cardiac enzyme or pericardial effusion observed after the proce-
dure. 2 pts died of stroke (8 mths) and myocardial infarction (20 mths), respectively. After
23±6 mths follow-up, there were significant improvement in NYHA class (2.1±0.8 vs
2.8±0.5), angina class (2±0.9 vs 3.3±0.5) and quality of life (SF-36: 65±14 vs 51±15)
compared to baseline (all p<0.05). Stress SPECT-sestamibi studies demonstrated signif-
icant improvement in myocardial perfusion in 9/12 (75%) pts at 6 mths. Magnetic reso-
nance imaging at baseline, 3 and 6 mths after procedure showed no evidence of
intramyocardial tumor formation, myocardial damage or change in left ventricular function
(58±9 vs 59±11 vs 58±16%, p>0.05). Furthermore, no patient developed symptomatic
ventricular tachyarrhythmias nor detected by 24 hrs Holter at 3 and 6 mths follow-up.
Conclusions: Our study demonstrate that BMC implantation using a percutaneous cath-
eter procedure is safe and feasible in pts with “end-staged” CAD and improve their symp-
toms and quality of life. The absence of any acute procedural complications or long-term
sequalae, including ventricular arrhythmia, myocardial damage or development of
intramyocardial tumor, are encouraging in terms of the safety and feasibility of this novel
catheter-based cellular transplantation procedure for severe CAD.
1025-65 First Human Heart Myoblast Allograft
Peter Law, Cell Transplants International, LLC, Memphis, TN
Background
Endomyocardial myoblast injections deposited myofilaments and augmented contractility.
We report here the world’s first myoblast allografts into two CAD patients.
Methods
Quadriceps biopsy (2.18g) from a 20-year-old, pathogen-free male was cultured comply-
ing cGMP/ISO 9001 to yield 3.64x109 myoblasts that were 98.3% pure (desmin immuno-
positive), 91.5% viable, potent in myotube formation, and negative for endotoxin, myco-
plasma, sterility, and gram stain. Male subjects, aged 63 and 49, developed atherosclero-
sis, coronary artery disease, chronic myocardial infarction, stable angina Functional
Class IV (CCS), and arterial hypertension II (risk 4). PET with 18FDG revealed scars with
hibernated myocardium in LV septal, apical, and anterior/posterior wall regions. Echocar-
diography showed regional akinesis/hypokinesis, LVEF being 41% and 38%. On 1/17/
2003, they received 18/19 injections and 1.1/1.2 billion myoblasts (108 /mL), respectively.
The 0.5 mL injections were placed between infarcted and viable myocardium after CABG
on ice-chilled, non-beating hearts. Subjects took oral cyclosporine (5 to 7 mg/kg body
weight per day) for 8 weeks. Doses were adjusted to maintain whole blood trough level at
about 250 ng/mL. 24-hour Holter EKG was monitored.
Results
The subjects recovered with no rash or high fever. Both developed arrhythmia and extra-
systoles that were eliminated with Amiodarone. Rejection symptom was not observed
despite cyclosporine discontinuation. Between 3 to 8-months follow-up, both were in sta-
ble condition with angina at Class I-II. Echocardiography showed 14.6% and 10.5%
increases in LVEF with no local hypokinesis. SPECT with 30 mCi 99mTc-tetrophosphomin
demonstrated positive dynamics, LVEF increases, and reduction in perfusion defect
areas during exercise and rest. 18FDG accumulation was equable throughout LV myocar-
dium; glucose metabolism sustained.
Conclusions
The feasibility and preliminary safety/efficacy shown in these allografts provide a new
potential therapy for heart failure and its prevention, with virtually unlimited cell availability
and 2-month immunosuppression.
1025-66 Biological Markers of the Restenosis
Laurent Payot, Gilles Montalescot, Rémi Choussat, Michel Slama, Jean-Luc Dubois 
Randé, Jean-Philippe Metzger, J. Thillet, C. Bal, L. Drouet, Centre Hospitalier 
Universitaire Pitié-Salpétrière (AP-HP), Paris, France
Background:
The incidence of coronary restenosis 6 months following angioplasty is 25 to 45%
according to selected definitions. The detection of restenosis by non-invasive means
remain particularly disappointing. The purpose of this study was to evaluate the evolution
of potential biological markers of restenosis after angioplasty and identify whether some
are predictive of restenosis.
Methods and Results:
A total of 229 consecutive patients with chronic stable angina or stabilised unstable
angina, were recruited in five centers. Measurements of fibrinogen, CRP, tPA Ag, VWfAg,
f PAI-1
f VIIc, f VIIa, f VII Ag, TAT, D-Dimer, Ceruloplasmine, lipoprotein(a) were performed in a
central laboratory before and immediately after, two months, four months and six months
after angioplasty. The criterion of evaluation was restenosis defined clinically and angio-
graphically. A systematic clinical and angiographic follow-up was obtained in all patients.
The relations between biological variables and definitions of restenosis were assessed
by univariate and multivariate analyses. A prolonged elevation of CRP and fibrinogen
was observed over the first four months of follow-up with some decrease at two month
and re ascension at four months( 32% increase of CRP between the second and fourth
month p=0.11; 4% increase of the fibrinogen, p=0.0022).A similar evolution was
observed for the plasma levels of f VIIc, f VII a, f VII Ag, f PAI. All the variables return to
baseline levels at six months. These biological profiles are consistent with the restenosis
process which occurs mainly between 2 and 4 months. However, after multivariate analy-
sis, no biological variable was significantly and consistently (with regards to the various
definitions) associated with restenosis, at any time point.
Conclusion: Ours findings suggest that inflammation occurs and can persist for 4 months
after angioplasty but no biological variable was found to be independently predictive of
clinical and/or angiographic restenosis.
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1026-55 In Vitro Detection and Quantification of High Intensity 
Transient Signals by Using Intracoronary Doppler 
Ultrasound: A New Approach to Detect Coronary 
Microembolization
Philipp Bahrmann, Marcel Wagner, Jens Hopfe, Markus Ferrari, Andreas Voss, Gerald S. 
Werner, Hans R. Figulla, Friedrich-Schiller-University, Jena, Germany, University of 
Applied Sciences, Jena, Germany
Introduction: Brief, high-intensity transient signals (HITS) in the Doppler velocity spec-
trum correspond to microemboli made of thrombotic and non-thrombotic material in labo-
ratory models. Transcranial doppler detection of HITS in the cerebral circulation was the
first clinical application to study the pathogenesis of embolism in humans. We used a
commercially available Doppler ultrasound device dedicated for the use in coronary arter-
ies for the validation of HITS detection in an in vitro model using artificial embolic parti-
cles.
Methods and Results: HITS were defined by the following characteristics: (1) high-
intensity signal, (2) short duration, (3) unidirectional within the Doppler velocity spectrum
and (4) accompanied by a "snap", "chirp" or "moan" on the audio output. An experimental
flow circuit was made of a polyethylene tube with an internal diameter of 3 mm. A flow
pattern similar to a human coronary artery was obtained by a roller pump. We positioned
a 0.014'' guidewire with a 12 MHz pulsed Doppler ultrasound transducer mounted on its
tip into the circuit. The guidewire was connected to a console (FloWire/FloMap System®,
Endosonics) that employed a 128-point fast Fourier transform for signal intensity mea-
